Ranirestat Market Forecasts and Outlook Report - 2022

Ranirestat (Microvascular Complications of Diabetes) – Forecast and
Market Analysis to 2022
by
GlobalData

Explore all reports for “Life Sciences” market
@
http://www.rnrmarketresearch.com/reports/life-sciences .

© RnRMarketResearch.com ;
sales@rnrmarketresearch.com ;
+1 888 391 5441

Ranirestat (Microvascular Complications of Diabetes) –
Forecast and Market Analysis to 2022
The entire market for micro vascular complications of diabetes (MCD) diabetic
nephropathy, retinopathy, and neuropathy is facing an extremely high level of
unmet need across the 7MM (US, 5EU and Japan). Despite its enormous
potential, the MCD market is facing the major global barrier in the sparsely
populated pipeline. The diabetic retinopathy segment of the market has recently
seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong
growth. On the other hand, the diabetic neuropathy and nephropathy segments
face the barrier in and increasing number of generic competitors.
Ranirestat is being developed jointly by Dainippon Sumitomo Pharma and Eisai
for the treatment of diabetic neuropathy. The drug is currently in Phase III trials
in Japan and recently completed Phase II/III trials in the US and Europe.
Ranirestat is a selective inhibitor of AR, a key enzyme in the polyol pathway
associated with the conversion of glucose to sorbitol.

Request a sample copy of this report @
http://www.rnrmarketresearch.com/contacts/request-sample?rname=147164
.
+1 888 391 5441


Scope
Overview of MCD, including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the competitive
landscape.
Detailed information on Ranirestat including product description, safety and
efficacy profiles as well as a SWOT analysis.
Sales forecast for Ranirestat from 2012 to 2022.
Sales information covered for Japan.
Complete report available @ http://www.rnrmarketresearch.com/ranirestatmicrovascular-complications-of-diabetes-forecast-and-market-analysis-to2022-market-report.html .

+1 888 391 5441

Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure
a robust return
Stay ahead of the competition by understanding the changing competitive
landscape for MCD
Effectively plan your M&A and partnership strategies by identifying drugs with
the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of
Ranirestat performance
Obtain sales forecast for Ranirestat from 2012-2022 in Japan.
Inquire for discount on this report @
http://www.rnrmarketresearch.com/contacts/discount?rname=147164 .

+1 888 391 5441

Table Of Contents
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
3 Disease Overview 13
3.1 Etiology and Pathophysiology 15
3.1.1 Diabetic Nephropathy 15
3.1.2 Diabetic Retinopathy 17
3.1.3 Diabetic Neuropathy 18
3.2 Prognosis 19
3.3 Quality of Life 20
3.4 Symptoms 21
+1 888 391 5441

4 Disease Management 22
4.1 Treatment Overview 22
4.1.1 Diagnosis and Referrals 22
4.1.2 Screening 24
4.1.3 Treatment Guidelines 25
5 Competitive Assessment 33
5.1 Overview 33
5.2 Strategic Competitor Assessment 34
6 Opportunity and Unmet Need 38
6.1 Overview 38
6.2 Unmet Needs 39
6.2.1 Unified Treatment for the Microvascular Complications of Diabetes 39
6.2.2 Optimization of Personalized Therapy in the Microvascular Complications
of Diabetes 39
6.2.3 Treatment for Diabetic Nephropathy that Would Prevent ESRD 41
6.2.4 Cardio- and Renoprotective Therapy for Diabetic Nephropathy 42
+1 888 391 5441

6.2.5 Efficient Therapy for Retinopathy 43
6.2.6 Convenient Administration in Diabetic Retinopathy Treatment 43
6.2.7 Treatment for Diabetic Neuropathy 44
6.3 Unmet Needs Gap Analysis 45
6.4 Opportunity: Therapy for the Underlying Cause of the Microvascular
Complications of Diabetes 47
6.5 Opportunity: Patient-Tailored Therapy for the Microvascular Complications of
Diabetes 47
6.6 Opportunity: Efficacious Therapy for Diabetic Nephropathy 48
6.7 Opportunity: Topical Treatment for Diabetic Retinopathy 48
6.8 Opportunity: Treatment for Diabetic Neuropathy 49
7 Pipeline Assessment 50
7.1 Overview 50
7.2 Promising Drugs in Clinical Development 52
Request a sample copy of this report @
http://www.rnrmarketresearch.com/contacts/request-sample?rname=147164
.
+1 888 391 5441

8 Ranirestat 54
8.1 Overview 54
8.2 Efficacy 55
8.3 Safety 56
8.4 Dosing and Formulation 56
8.5 Potential Clinical Positioning 56
8.6 Potential Commercial Positioning 57
8.7 Pricing and Reimbursement 57
8.8 SWOT Analysis 57
8.9 Forecast 58
9 Appendix 59
9.1 Bibliography 59
9.2 Abbreviations 63
9.3 Methodology 65
9.4 Forecasting Methodology 65
9.4.1 Diagnosed Patients 65
9.4.2 Percent Drug-Treated Patients 66
+1 888 391 5441

9.4.3 General Pricing Assumptions 66
9.4.4 Generic Erosion 67
9.4.5 Pricing of Pipeline Agents 67
9.5 Physicians and Specialists Included in this Study 68
9.6 About the Authors 70
9.6.1 Analyst II - CVMD 70
9.6.2 Therapy Director - CVMD and Infectious Disease 70
9.6.3 Global Head of Healthcare 71
9.7 About GlobalData 72
9.8 Disclaimer 72
List of Tables
Table 1: Risk Factors for MCD 15
Table 2: Symptoms of MCD 21
Table 3: Diagnostic Tests and Typical Criteria for MCD 23
Table 4: Treatment Guidelines for MCD 26
Table 5: Most Prescribed Drugs for MCD by Class in the 7MM, 2012 29
Table 6: Leading Drug Treatments for MCD, 2013 36
+1 888 391 5441

Table 7: Overall Unmet Needs - Current Level of Attainment 38
Table 8: Clinical Unmet Needs in MCD - Gap Analysis, 2012 46
Table 9: MCD - Phase Pipeline, 2013 52
Table 10: Comparison of Drugs in Development for MCD, 2013 53
Table 11: Product Profile - Ranirestat 55
Table 12: Ranirestat SWOT Analysis, 2013 57
Table 13: Global Sales Forecasts ($m) for Ranirestat, 2012-2022 58
Table 14: Number of High-Prescribing Physicians Surveyed 69
List of Figures
Figure 1: Potential Mechanisms of Diabetes-Induced Microvascular
Complications 14
Figure 2: General Treatment Algorithms for MCD 27
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in MCD, 20122022
Inquire for discount on this report @
http://www.rnrmarketresearch.com/contacts/discount?rname=147164 .
+1 888 391 5441

Ranirestat (Microvascular Complications of Diabetes) – Forecast
and Market Analysis to 2022

For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com /
+18883915441

RnR Market Research
RnRMarketResearch.com, an online repository of market research reports, offers in-depth
analysis of over 5000 market segments. RnR Market Research library has syndicated reports by
leading market research publishers across the globe.

+1 888 391 5441

Ranirestat Market Forecasts and Outlook Report - 2022

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

Empfohlen

Empfohlen (20)

Ranirestat Market Forecasts and Outlook Report - 2022